Literature DB >> 12372798

Altered expression of skeletal muscle myosin isoforms in cancer cachexia.

Gary M Diffee1, Katherine Kalfas, Sadeeka Al-Majid, Donna O McCarthy.   

Abstract

Cachexia is commonly seen in cancer and is characterized by severe muscle wasting, but little is known about the effect of cancer cachexia on expression of contractile protein isoforms such as myosin. Other causes of muscle atrophy shift expression of myosin isoforms toward increased fast (type II) isoform expression. We injected mice with murine C-26 adenocarcinoma cells, a tumor cell line that has been shown to cause muscle wasting. Mice were killed 21 days after tumor injection, and hindlimb muscles were removed. Myosin heavy chain (MHC) and myosin light chain (MLC) content was determined in muscle homogenates by SDS-PAGE. Body weight was significantly lower in tumor-bearing (T) mice. There was a significant decrease in muscle mass in all three muscles tested compared with control, with the largest decrease occurring in the soleus. Although no type IIb MHC was detected in the soleus samples from control mice, type IIb comprised 19% of the total MHC in T soleus. Type I MHC was significantly decreased in T vs. control soleus muscle. MHC isoform content was not significantly different from control in plantaris and gastrocnemius muscles. These data are the first to show a change in myosin isoform expression accompanying muscle atrophy during cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372798     DOI: 10.1152/ajpcell.00154.2002

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  39 in total

Review 1.  Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.

Authors:  Benjamin H L Tan; James A Ross; Stein Kaasa; Frank Skorpen; Kenneth C H Fearon
Journal:  J Genet       Date:  2011-04       Impact factor: 1.166

Review 2.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

3.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

4.  NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo.

Authors:  Ashley Wysong; Marion Couch; Scott Shadfar; Luge Li; Lugi Li; Jessica E Rodriguez; Scott Asher; Xiaoying Yin; Mitchell Gore; Al Baldwin; Cam Patterson; Monte S Willis
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

6.  Cancer cachexia decreases specific force and accelerates fatigue in limb muscle.

Authors:  B M Roberts; G S Frye; B Ahn; L F Ferreira; A R Judge
Journal:  Biochem Biophys Res Commun       Date:  2013-05-11       Impact factor: 3.575

7.  Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia.

Authors:  Hirak Der-Torossian; Ashley Wysong; Scott Shadfar; Monte S Willis; Jonathan McDunn; Marion E Couch
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-01-24       Impact factor: 12.910

8.  Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia.

Authors:  Kyle R Bohnert; Yann S Gallot; Shuichi Sato; Guangyan Xiong; Sajedah M Hindi; Ashok Kumar
Journal:  FASEB J       Date:  2016-05-20       Impact factor: 5.191

9.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.

Authors:  Swarnali Acharyya; Katherine J Ladner; Lori L Nelsen; Jeffrey Damrauer; Peter J Reiser; Steven Swoap; Denis C Guttridge
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy.

Authors:  Samantha A Whitman; Min Long; Georg T Wondrak; Hongting Zheng; Donna D Zhang
Journal:  Exp Cell Res       Date:  2013-07-27       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.